FEBRUARY, 2009

PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE - PRESS RELEASE

IN LINE WITH ITS STRATEGY OF INTERNATIONAL DEVELOPMENT, VALOIS PHARMA IS INVESTING IN ITS MANUFACTURING FACILITY AT VALOIS OF AMERICA'S CONGERS SITE IN THE UNITED STATES.

World leader in nasal and pulmonary drug delivery devices, Valois Pharma is developing expertise and expanding production capacity at its Congers, New York facility in the U.S.

"Local manufacturing": real added-value for Valois of America's clients

There are two main stages in the manufacture of nasal spray drug delivery devices (nasal pumps): precision injection molding of plastic components, and high-speed assembly of components and sub-assemblies. Until now, nasal pump components manufactured at the Congers site were molded in Europe and assembled at Congers. However, molding is now being integrated into the Congers site's manufacturing process, upstream of assembly. This will allow Valois Pharma to better meet its North American clients' business expectations and help these clients grow their own markets.

Local manufacturing will bring real benefits to Valois of America's clients. The gain in autonomy of the Congers nasal pump production processes will result in a more reactive supply chain, better adapted to clients' needs.

A significant investment by Valois Pharma in this ambitious project

Integration of molding and expansion of Valois of America's site represent a significant investment for Valois Pharma. The initial phase of the project, which started at the end of 2008 and will be completed at the end of 2009, includes the creation of a molding workshop, the construction of a new ISO 7 cleanroom, and the acquisition of injection presses. The second phase of the project will see installation of additional manufacturing capacity to cope with expected market growth.

Overall, the scale-up is expected to last 3 years with completion in 2011. This expansion will create an estimated 30 new jobs.

The industrial expansion at Valois of America's Congers site is part of Valois Pharma's international strategy to continuously develop and modernize its 4 manufacturing facilities: Congers in the U.S., Le Vaudreuil - Val de Reuil in France, Lugano in Switzerland and Suzhou in China.

Valois Pharma, a division of Valois S.A.S, specializes in nasal and pulmonary drug delivery technologies with a broad product range that also provides solutions for other drug delivery routes such as buccal/sub-lingual, throat and dermal/transdermal.

Valois S.A.S., founded in 1947, is a world leader in the design, development and manufacture of proprietary spray, aerosol and alternative dispensing systems for the Pharmaceutical, Perfumery and Cosmetics markets. Valois S.A.S. is a wholly owned subsidiary of AptarGroup, Inc., a publicly traded company listed on the New York Stock Exchange (NYSE: ATR).

Press contact:

Marie-Cécile Lachaux-Disle, press manager
Tel.: +33 (0)1 39 17 20 41 - **Fax:** +33 (0)1 39 58 12 98 - **Email:** marie-cecile.lachaux-disle@valois.com